Share your videos with the world

Sign Up | Log In | Help  

   
 
Related Tags: nma  national  meningitis  association  health  vaccines  educate  meningitis  awareness  multivu  8385951  sanofi  vaccines  health  treatment  fluzone  flu  fda  medical  healthcare  multivu  8081151  medical  vaccines  seqirus  influenza  technology  fluad  cure  afluria  fluvirin  multivu  7902351  flu  vaccine  health  healthcare  fluzone  fda  pharmacies  sanofi  medical  multivu  7842051  flu  vaccine  seqirus  college  students  health  safety  awareness  season  multivu  7833751  health  medicine  company  chemicals  drugs  cancer  diabetes  disease  treatment  multivu  7809951  sports  paralympian  lenine  cunha  competition  meningitis  diseases  meningococcal  paralympics  meningitis  multivu  7814851  children  pneumonia  health  disease  united  nations  vaccine  awareness  donations  immunization  programs  multivu  7616651  ddn  storage  datadirect  networks  big  storage  scalable  storage  virginia  bioinformatics  institute  ebola  multivu  7429756  influenza  flu  flumist  quadrivalent  astrazeneca  james  van  der  beek  vaccine  multivu  7312451  issels  integrative  immunotherapy  lung  cancer  alternative  treatment  remission  vaccines  cell  therapy  multivu  65511  issels  integrative  cancer  treatment  autologous  vaccine  cell  therapy  remission  immunotherapy  health  multivu  64826 
Search // vaccine
Results 1-12 of 21 for ' vaccine ' (0 seconds)
The National Meningitis Association (NMA) today announced the launch of a new educational initiative in collaboration with Sanofi Pasteur, the vaccines division of Sanofi, about the importance of the Centers for Disease Control and Prevention’s (CDC’s) recommended second dose of the meningococcal meningitis vaccine (MenACWY) for adolescents at age 16. The 16 Vaccine (The16Vaccine.org) aims to educate parents about the importance of this critical second dose of MenACWY, which helps protect teens against meningococcal meningitis during the period when they are at increased risk. To view the multimedia release go to: https://www.multivu.com/players/English/8385951-national-meningitis-association-the-16-vaccine/
Categories // Miscellaneous 
Added: 569 days ago by MultiVuVideos
Runtime: 1m44s | Views: 40 | Comments: 0
Not yet rated
 

 

 

Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today that its first doses of the Fluzone® (Influenza Vaccine) portfolio for the 2017-2018 influenza (“flu”) season have been released by the U.S. Food and Drug Administration (FDA). Sanofi Pasteur has begun distributing initial shipments, representing the first of nearly 70 million total doses of seasonal influenza vaccine manufactured by the company for this upcoming influenza season. Widespread shipment of Fluzone Quadrivalent, Fluzone High-Dose and Fluzone Intradermal Quadrivalent vaccine to health care provider offices, pharmacies and other immunizers will begin in early August to support fall immunization campaigns. “As we enter the Swiftwater site’s 120th year, it reminds us of our innovation and growth as we came to understand the science of influenza and its impact on human health,” said David P. Greenberg, M.D., Associate Vice President and Regional Medical Head North America, Sanofi Pasteur. “Influenza can be especially severe for the most vulnerable populations, including the elderly, young children and those with compromised immune systems; however, it can also have a serious health impact on otherwise healthy individuals. Sanofi Pasteur is and always has been deeply committed to improving public health by continuously striving to develop new vaccines and on improving existing ones.” To view the multimedia release go to: https://www.multivu.com/players/English/8081151-sanofi-pasteur-influenza-vaccine-first-shipment-2017/
Categories // Miscellaneous 
Added: 996 days ago by MultiVuVideos
Runtime: 1m27s | Views: 39 | Comments: 1
Not yet rated
 

 

 

Seqirus is now shipping its complete portfolio of seasonal influenza vaccines to customers in the US market for the 2016-2017 season. Seqirus is the only influenza vaccine manufacturer to produce influenza vaccines using both egg-based and cell culture technologies, and the only provider in the US that offers both quadrivalent and trivalent influenza vaccines, as well as the only adjuvanted seasonal influenza vaccine. Seqirus is now shipping to the US all influenza vaccines in its portfolio, including Fluad™ (Influenza Vaccine, Adjuvanted), Flucelvax Quadrivalent™ (Influenza Vaccine), Afluria® (Influenza Vaccine), and Fluvirin® (Influenza Virus Vaccine) in advance of the peak of influenza season. “Seqirus is proud to be a major contributor to the prevention and control of influenza by offering healthcare providers and pharmacists with a range of clinically proven, innovative vaccination options that help protect people against the debilitating effects of the disease,” said Brent MacGregor, Senior Vice President, Commercial Operations. “We are committed to being an early and reliable supplier of our influenza vaccines to help ensure that appropriate patients have plenty of time to get their annual immunization.” To view the multimedia release go to: http://www.multivu.com/players/English/7902351-seqirus-franchise-shipment/
Categories // Miscellaneous 
Added: 1330 days ago by MultiVuVideos
Runtime: 5m12s | Views: 153 | Comments: 0
Not yet rated
 

 

 

Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today that its first doses of Fluzone® (Influenza Vaccine) for the 2016-2017 influenza (“flu”) season have been released by the U.S. Food and Drug Administration (FDA) for shipment. This represents the first of more than 65 million total doses of seasonal influenza vaccine manufactured by Sanofi Pasteur that will be delivered to U.S. health care providers and pharmacies beginning in July and continuing throughout the remainder of the year. Sanofi Pasteur plans to increase its supply to respond to the shifting pediatric public health needs. Seasonal influenza activity typically occurs between October and May and peaks between December and February. However, influenza activity peaked noticeably late last season occurring in early March 2016.1 Influenza seasons are always unpredictable as new influenza strains emerge and strain activity fluctuates throughout the year, making timely vaccination even more important to help protect against the virus, especially for seniors, young children and infants six months of age and older. To view the multimedia release go to: http://www.multivu.com/players/English/7842051-sanofi-pasteur-influenza-vaccine/
Categories // Miscellaneous 
Added: 1353 days ago by MultiVuVideos
Runtime: 4m50s | Views: 212 | Comments: 0
Not yet rated
 

 

 

Seqirus announced today that the National Adult and Influenza Immunization Summit (NAIIS) awarded the organization with the 2016 Immunization Excellence Award for best Corporate Campaign. The accolade recognizes Seqirus’ creative and collaborative efforts to improve vaccination awareness and rates during the 2015-16 influenza season. The award was presented yesterday during the NAIIS Summit in Atlanta, Georgia. “We are pleased to receive this prestigious honor, and thankful to our partners, Families Fighting Flu and several collegiate student organizations, for their dedication to spreading the word about the dangers of flu and encouraging their peers to get vaccinated,” said Dr. Marie Mazur, Vice President of Global Commercial Development and Policy. “Moving forward, Seqirus is committed to building on this season’s success with college students and continuing the important work of flu prevention for all.” To view the multimedia release go to: http://www.multivu.com/players/English/7833751-seqirus-national-award-knockoutflu/
Categories // Miscellaneous 
Added: 1427 days ago by MultiVuVideos
Runtime: 0m54s | Views: 210 | Comments: 0
Not yet rated
 

 

 

Eli Lilly and Company (NYSE: LLY) will commemorate its 140th anniversary today with activities at Lilly locations worldwide, including a ceremony to unveil a statue dedicated to founder Colonel Eli Lilly at global headquarters in Indianapolis. Over 14 decades, the organization has contributed more than 100 medicines and significant medical advances, such as the first commercially available insulin, manufacturing and global distribution of the Salk polio vaccine and mental health breakthroughs such as anti-depressant Prozac® (fluoxetine). Today Lilly continues to progress its most robust pipeline in history with dozens of potential new medicines in mid- to late-stage development for cancer, diabetes, autoimmune disease, pain and Alzheimer’s disease. “As Lilly celebrates 140 years, we’re keeping the vision of our founder alive – from our dedication in the lab to our impact in the community,” said John C. Lechleiter, Ph.D., Lilly chairman, president and chief executive officer, who began his career at Lilly as a chemist in 1979. “Colonel Eli Lilly started this company to put science to work fighting disease and encouraged his successors to ‘take what you find here and make it better and better.’ That vision pushes us daily to honor Colonel Lilly’s legacy and continue in our quest to discover new medicines to help make life better.” To view the multimedia release go to: http://www.multivu.com/players/English/7809951-eli-lilly-and-company-140th-anniversary/
Categories // Miscellaneous 
Added: 1430 days ago by MultiVuVideos
Runtime: 2m30s | Views: 172 | Comments: 0
Not yet rated
 

 

 

An international survey conducted by GSK and released for World Meningitis Day shows gaps in the knowledge parents feel they have about meningococcal disease and its potential consequences. Almost 7 in 10 parents said they don’t know enough about the different strains of meningococcal disease and the potential damage they can cause. On average, more than half of parents were either unsure or unaware that there are different types of bacteria that cause the disease. The survey of 5,000 parents in Brazil, Canada, Germany, Italy and Portugal also shows that out of a list of 14 vaccine-preventable diseases, meningococcal disease is considered by many parents to pose a top three health risk to their children. Fifty-seven percent listed meningococcal disease among the top three health conditions they considered of greatest risk to children followed by Hepatitis B at 34 percent, pneumococcal disease at 27 percent, polio at 25 percent, tetanus at 20 percent and pertussis at 17 percent. A sudden, potentially life-threatening illness, meningococcal disease kills on average one person every eight minutes worldwide. It typically manifests as bacterial meningitis – an infection of the membrane around the brain and spine; or bacteraemia – a bloodstream infection. The disease progresses rapidly and it can lead to death within 24-48 hours of the first symptoms; globally up to 1 in 10 of those infected may die and in the US about 10-15 percent of people will die. To view the multimedia release go to: http://www.multivu.com/players/uk/7814851-gsk-survey-world-meningitis-day/
Categories // Miscellaneous 
Added: 1445 days ago by MultiVuVideos
Runtime: 0m21s | Views: 186 | Comments: 0
Not yet rated
 

 

 

The United Nations Foundation’s Shot@Life campaign marks World Pneumonia Day, November 12, by asking Americans to raise awareness, funds and advocate to members of Congress to support global immunization programs. Pneumonia kills nearly a million children under the age of five each year and almost half of those deaths are vaccine-preventable. “Around the world one in five children lack access to the vaccines they need,” said Devi Thomas, Director, UN Foundation’s Shot@Life campaign. “By raising awareness, funding and asking members of Congress to support global immunization programs we can ensure that every child, no matter where they live, is given a shot at a healthy life.” To view the multimedia release go to: http://www.multivu.com/players/English/7616651-shotatlife-united-nations-vaccines/
Categories // Miscellaneous 
Added: 1609 days ago by MultiVuVideos
Runtime: 0m39s | Views: 210 | Comments: 0
Not yet rated
 

 

 

Virginia Bioinformatics Institute (VBI), a world-class research institute dedicated to the study of information biology, is using DataDirect Networks (DDN) SFA® high-performance storage engine-based GRIDScaler GPFS parallel file system to perform rapid, accurate Ebola outbreak modeling for the U.S. Department of Defense’s Defense Threat Reduction Agency (DTRA). A team of 30 researchers and scientists on VBI’s Ebola rapid response team initially provided DTRA and West Africa’s Ministries of Health (MOH) with short-term forecasts on vaccine production and disease spread. To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7429756-ddn-gridscaler-vbi-ebola/
Added: 1870 days ago by MultiVuVideos
Runtime: 3m38s | Views: 336 | Comments: 2
Not yet rated
 

 

 

AstraZeneca announced today that it has collaborated with actor and father James Van Der Beek on a campaign to dispel common myths about the flu and underscore the importance of annual influenza vaccination for eligible individuals and families. As part of the campaign, Van Der Beek stars in an informative and comedic video, called “Just the Flu Facts,” in which he uses his signature sense of humor to debunk common misconceptions about seasonal influenza that are often barriers to vaccination. To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7312451-medimmune-specialty-care-james-van-der-beek-flumist-quadrivalent-encourage-flu-shot/
Categories // Miscellaneous 
Added: 2032 days ago by MultiVuVideos
Runtime: 2m50s | Views: 356 | Comments: 0
Not yet rated
 

 

 

Lung cancer is the most common cause of cancer-related death worldwide, with the highly malignant small cell lung cancer having the worst prognosis. In recent years the surge of immunotherapy has given cancer sufferers new hope. To view the Multimedia News Release, go to http://www.multivu.com/mnr/64826-issels-recurrent-lung-cancer-responds-to-integrative-immunotherapy
Added: 2303 days ago by MultiVuVideos
Runtime: 4m34s | Views: 860 | Comments: 1
Not yet rated
 

 

 

In recent years there has been a shift in the understanding of cancer. Immunotherapy with vaccines has been emerging as the most promising direction towards a decisive improvement of treatment outcomes. The Dendritic Cell Vaccine has received FDA approval for prostate cancer and trials are now under way for a variety of other cancers. These vaccines are usually administered on their own. To view Multimedia News Release, go to http://www.multivu.com/mnr/64654-issels-integrative-immunotherapy-for-standard-therapy-resistant-cancers
Categories // People and Blog 
Added: 2317 days ago by MultiVuVideos
Runtime: 4m46s | Views: 436 | Comments: 1
Not yet rated
 

 

 

Page 1 of 2  |  Go to page    Next» LAST»»



About Us   |   Help  |   Advertise on ClipMoon   |   Terms of Use   |   Privacy Policy   |   Copyright   |   Contact   |   Link us   |   RSS 
Copyright © 2007-2020 ClipMoon.com. All rights reserved.